ArticleHaematologica2025

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Gabriel Brisou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.